{"id":43465,"date":"2025-10-15T17:32:05","date_gmt":"2025-10-15T09:32:05","guid":{"rendered":"https:\/\/flcube.com\/?p=43465"},"modified":"2025-10-15T17:32:06","modified_gmt":"2025-10-15T09:32:06","slug":"sino-biopharmaceuticals-partner-cttq-secures-breakthrough-therapy-designation-for-tq%e2%80%91b3234-capsule-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43465","title":{"rendered":"Sino\u202fBiopharmaceutical\u2019s Partner CTTQ Secures Breakthrough Therapy Designation for TQ\u2011B3234 Capsule in China"},"content":{"rendered":"\n<p><strong>Jiangsu\u202fChia\u202fTai Tianqing Pharmaceutical Co.,\u202fLtd.<\/strong> (CTTQ), a subsidiary of China\u2011based <strong>Sino Biopharmaceutical Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>), today announced that its Class\u202f1 innovative drug <strong>TQ\u2011B3234 Capsule<\/strong>\u2014a selective MEK1\/2 inhibitor co\u2011developed with <strong>Shouyao Holdings<\/strong>\u2014has been granted <strong>Breakthrough Therapy Designation<\/strong> in China. The indication is the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adults with <strong>Neurofibromatosis Type\u202f1 (NF1)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-tq-b3234\">About TQ\u2011B3234<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug class<\/strong><\/td><td>Selective MEK1\/2 inhibitor<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>RAS\u2011RAF\u2011MEK\u2011ERK signaling pathway<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Symptomatic, inoperable PN in adult NF1 patients<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Chinese Breakthrough Therapy (BT) status<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 Inhibits MEK1\/2, upstream regulators of ERK, thereby suppressing tumor growth driven by RAS\u2011mutated pathways.<\/li>\n\n\n\n<li><strong>Clinical promise<\/strong> \u2013 Offers a non\u2011surgical therapeutic option for a disease where surgery is often high\u2011risk and prone to recurrence.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-context-neurofibromatosis-type-1\">Context: Neurofibromatosis Type\u202f1<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Genetics<\/strong> \u2013 Autosomal dominant disorder caused by NF1 gene mutations; accounts for ~96\u202f% of neurofibromatosis cases.<\/li>\n\n\n\n<li><strong>Incidence<\/strong> \u2013 ~5 per million live births in China (2023 data).<\/li>\n\n\n\n<li><strong>Rare\u2011Disease Status<\/strong> \u2013 Added to China\u2019s \u201cSecond National List of Rare Diseases\u201d in September\u202f2023.<\/li>\n\n\n\n<li><strong>Clinical burden<\/strong> \u2013 30\u201360\u202f% of NF1 patients develop plexiform neurofibromas, a leading cause of pain, disfigurement, and malignant transformation.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-significance-of-breakthrough-therapy-designation\">Significance of Breakthrough Therapy Designation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Development<\/strong> \u2013 Enables faster regulatory review and priority access to clinical trial data.<\/li>\n\n\n\n<li><strong>Patient Impact<\/strong> \u2013 Potential to fill a critical unmet need for adults with inoperable PN.<\/li>\n\n\n\n<li><strong>Strategic Advantage<\/strong> \u2013 Positions CTTQ and Sino\u202fBiopharmaceutical at the forefront of rare\u2011disease drug development in China.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu\u202fChia\u202fTai Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a subsidiary of China\u2011based Sino Biopharmaceutical Ltd. (HKG: 1177), today&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43467,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[11],"tags":[34,661,908,24,344,313],"class_list":["post-43465","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug","tag-breakthrough-therapy","tag-chia-tai-tianqing-pharmaceutical","tag-hkg-1177","tag-rare-orphan-disease-drugs","tag-shouyao-holdings","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino\u202fBiopharmaceutical\u2019s Partner CTTQ Secures Breakthrough Therapy Designation for TQ\u2011B3234 Capsule in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu\u202fChia\u202fTai Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a subsidiary of China\u2011based Sino Biopharmaceutical Ltd. (HKG: 1177), today announced that its Class\u202f1 innovative drug TQ\u2011B3234 Capsule\u2014a selective MEK1\/2 inhibitor co\u2011developed with Shouyao Holdings\u2014has been granted Breakthrough Therapy Designation in China. The indication is the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adults with Neurofibromatosis Type\u202f1 (NF1).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43465\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino\u202fBiopharmaceutical\u2019s Partner CTTQ Secures Breakthrough Therapy Designation for TQ\u2011B3234 Capsule in China\" \/>\n<meta property=\"og:description\" content=\"Jiangsu\u202fChia\u202fTai Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a subsidiary of China\u2011based Sino Biopharmaceutical Ltd. (HKG: 1177), today announced that its Class\u202f1 innovative drug TQ\u2011B3234 Capsule\u2014a selective MEK1\/2 inhibitor co\u2011developed with Shouyao Holdings\u2014has been granted Breakthrough Therapy Designation in China. The indication is the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adults with Neurofibromatosis Type\u202f1 (NF1).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43465\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-15T09:32:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T09:32:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1516.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43465#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43465\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino\u202fBiopharmaceutical\u2019s Partner CTTQ Secures Breakthrough Therapy Designation for TQ\u2011B3234 Capsule in China\",\"datePublished\":\"2025-10-15T09:32:05+00:00\",\"dateModified\":\"2025-10-15T09:32:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43465\"},\"wordCount\":273,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43465#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1516.webp\",\"keywords\":[\"Breakthrough therapy\",\"Chia Tai Tianqing Pharmaceutical\",\"HKG: 1177\",\"Rare \\\/ orphan disease drugs\",\"Shouyao Holdings\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43465#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43465\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43465\",\"name\":\"Sino\u202fBiopharmaceutical\u2019s Partner CTTQ Secures Breakthrough Therapy Designation for TQ\u2011B3234 Capsule in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43465#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43465#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1516.webp\",\"datePublished\":\"2025-10-15T09:32:05+00:00\",\"dateModified\":\"2025-10-15T09:32:06+00:00\",\"description\":\"Jiangsu\u202fChia\u202fTai Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a subsidiary of China\u2011based Sino Biopharmaceutical Ltd. (HKG: 1177), today announced that its Class\u202f1 innovative drug TQ\u2011B3234 Capsule\u2014a selective MEK1\\\/2 inhibitor co\u2011developed with Shouyao Holdings\u2014has been granted Breakthrough Therapy Designation in China. The indication is the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adults with Neurofibromatosis Type\u202f1 (NF1).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43465#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43465\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43465#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1516.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1516.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino\u202fBiopharmaceutical\u2019s Partner CTTQ Secures Breakthrough Therapy Designation for TQ\u2011B3234 Capsule in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43465#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino\u202fBiopharmaceutical\u2019s Partner CTTQ Secures Breakthrough Therapy Designation for TQ\u2011B3234 Capsule in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino\u202fBiopharmaceutical\u2019s Partner CTTQ Secures Breakthrough Therapy Designation for TQ\u2011B3234 Capsule in China - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu\u202fChia\u202fTai Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a subsidiary of China\u2011based Sino Biopharmaceutical Ltd. (HKG: 1177), today announced that its Class\u202f1 innovative drug TQ\u2011B3234 Capsule\u2014a selective MEK1\/2 inhibitor co\u2011developed with Shouyao Holdings\u2014has been granted Breakthrough Therapy Designation in China. The indication is the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adults with Neurofibromatosis Type\u202f1 (NF1).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43465","og_locale":"en_US","og_type":"article","og_title":"Sino\u202fBiopharmaceutical\u2019s Partner CTTQ Secures Breakthrough Therapy Designation for TQ\u2011B3234 Capsule in China","og_description":"Jiangsu\u202fChia\u202fTai Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a subsidiary of China\u2011based Sino Biopharmaceutical Ltd. (HKG: 1177), today announced that its Class\u202f1 innovative drug TQ\u2011B3234 Capsule\u2014a selective MEK1\/2 inhibitor co\u2011developed with Shouyao Holdings\u2014has been granted Breakthrough Therapy Designation in China. The indication is the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adults with Neurofibromatosis Type\u202f1 (NF1).","og_url":"https:\/\/flcube.com\/?p=43465","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-15T09:32:05+00:00","article_modified_time":"2025-10-15T09:32:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1516.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43465#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43465"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino\u202fBiopharmaceutical\u2019s Partner CTTQ Secures Breakthrough Therapy Designation for TQ\u2011B3234 Capsule in China","datePublished":"2025-10-15T09:32:05+00:00","dateModified":"2025-10-15T09:32:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43465"},"wordCount":273,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43465#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1516.webp","keywords":["Breakthrough therapy","Chia Tai Tianqing Pharmaceutical","HKG: 1177","Rare \/ orphan disease drugs","Shouyao Holdings","Sino Biopharmaceutical"],"articleSection":["Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43465#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43465","url":"https:\/\/flcube.com\/?p=43465","name":"Sino\u202fBiopharmaceutical\u2019s Partner CTTQ Secures Breakthrough Therapy Designation for TQ\u2011B3234 Capsule in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43465#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43465#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1516.webp","datePublished":"2025-10-15T09:32:05+00:00","dateModified":"2025-10-15T09:32:06+00:00","description":"Jiangsu\u202fChia\u202fTai Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a subsidiary of China\u2011based Sino Biopharmaceutical Ltd. (HKG: 1177), today announced that its Class\u202f1 innovative drug TQ\u2011B3234 Capsule\u2014a selective MEK1\/2 inhibitor co\u2011developed with Shouyao Holdings\u2014has been granted Breakthrough Therapy Designation in China. The indication is the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adults with Neurofibromatosis Type\u202f1 (NF1).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43465#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43465"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43465#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1516.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1516.webp","width":1080,"height":608,"caption":"Sino\u202fBiopharmaceutical\u2019s Partner CTTQ Secures Breakthrough Therapy Designation for TQ\u2011B3234 Capsule in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43465#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino\u202fBiopharmaceutical\u2019s Partner CTTQ Secures Breakthrough Therapy Designation for TQ\u2011B3234 Capsule in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1516.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43465"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43465\/revisions"}],"predecessor-version":[{"id":43469,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43465\/revisions\/43469"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43467"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}